A synthetic 31-amino-acid research peptide in the GLP-1 receptor agonist class. A crystalline solid, supplied as a single-lot reference material.
Vial size
$28.80
5 mg / vial · $5.76 / mg
Quantity
Add 1 more for 3% off
Bundle & save
1 vial
$28.80
each
2 vials
$27.94
3% off
3+ vials
$27.36
5% off
Per-vial price shown. The discount applies automatically at checkout.
Purchase options
Verification
Every batch is identified by a lot number, and its third-party certificate is listed here by lot. Measured values are shown only when they are real and independently verifiable.
Third-party testing in progress
We are currently having this product independently tested by a third-party laboratory. Its certificate of analysis will be published here as soon as the results are available — please check back soon. For laboratory research use only.
Semaglutide is a synthetic research peptide of thirty-one amino acids in the GLP-1 receptor agonist class, built on the frame of a natural incretin hormone. It is one of the most studied compounds in the incretin research collection.
Vestrand supplies it as one production lot at a time, each batch made ready for independent purity testing, and the certificate for that lot is published to its verification page once analysis is complete.
Because several incretin compounds look alike on paper, the dependable way to know exactly what a vial holds is its per-lot certificate rather than the name — which is precisely what Vestrand documents. Purity is stated as one specification and verified for each lot.
For laboratory research use only. Not for human or veterinary use.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, an acylated analogue built on the incretin-hormone backbone. It sits within incretin and metabolic-pathway research as a single-target reference point in the GLP-1 receptor agonist class.
Independent peer-reviewed literature that references Semaglutide.
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies M et al.
Lancet2021
View source for Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (opens in a new tab)Semaglutide for the treatment of obesity
Chao AM et al.
Trends Cardiovasc Med2023
View source for Semaglutide for the treatment of obesity (opens in a new tab)Safety of Semaglutide
Smits MM et al.
Front Endocrinol (Lausanne)2021
View source for Safety of Semaglutide (opens in a new tab)Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Tan HC et al.
J ASEAN Fed Endocr Soc2022
View source for Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (opens in a new tab)Citations are provided for educational and scientific reference only. They describe independent published research and are not product claims — they do not represent the performance, purity, or intended use of any material offered for sale.
General handling guidance for laboratory research materials — always defer to the product label and the lot certificate of analysis.
Research use only
For laboratory research use only. Not for human or veterinary use.
No reviews yet
Reviews are published only from verified purchases, so none appear until orders ship.
Peptide
A short synthetic peptide corresponding to a tail-end fragment of human growth hormone, with one extra building block added at the front.
Peptide
A synthetic peptide of fifteen building blocks (a pentadecapeptide), based on a partial sequence of a protein first identified in gastric juice.
Peptide blend
A blend of two peptides — BPC-157 and TB-500 — supplied together. A mixture, not a single substance, with no identity of its own.
Peptide
A growth-hormone-releasing factor analogue of twenty-nine building blocks, also known as Modified GRF (1-29). Easily confused with the closely related sermorelin.